MoneyWorks4Me

Wintac Ltd (524758)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 524758 NSE: Pharmaceuticals & Drugs | Small Cap | Wintac Share Price

₹341.60 0.00 (0.00%)

As on 17-Dec'20 18:59

Wintac Ltd (524758)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 524758 NSE: Pharmaceuticals & Drugs | Small Cap | Wintac Share Price

₹341.60 0.00 (0.00%)

As on 17-Dec'20 18:59

Key Metrics
Valuation Multiples
Market Cap
₹342 Cr.
Current Price
₹341.6
52-Week Low / High
₹336 / 345
TTM EPS
-
TTM Sales
-
Book Value per Share
-
P/E Ratio
Industry PE
54.8
Price to Book (P/B)
Price to Sales (P/S)
EV/EBITDA
Dividend Yield
0%
Profitability Efficiency
Return on Equity (ROE)
%
Return on Capital Employed (ROCE)
%
Return on Assets (ROA)
%
Operating Profit Margin
0%
Net Profit Margin
-%
Gross Profit Margin
0%
Growth Momentum
1-yr vs 3-yr growth
Sales Growth (1 Year)
Improving versus 3-year growth rate
70.32%
Operating Profit Growth (1 Year)
-
-
Net Profit Growth (1 Year)
-
-
Asset Quality
Promoter Holding
54.99%
Pledged shares (%) of Promoter's holding (%)
0.00%
Reserves
-
Equity
₹10 Cr.
Face Value
₹10
All Time Low / High
₹6.33 / 397.80

Wintac stock performance

Key Ratios
mw4me loader

10 Year X-Ray :

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Wintac Ltd has not performed well majority of the past ten years indicating its past ten year financial track record is not good

Value Creation ⓘ

Mar'12Mar'13Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21TTM
ROCE % ⓘ-4.9%-33.6%-14.6%-22.8%-57.6%-46.4%-109.9%3.5%-4.2%72%-
Value Creation
Index ⓘ
-1.4-3.4-2.0-2.6-5.1-4.3NA-0.8NA4.2-

Growth Parameters ⓘ

Sales ⓘ24.320.930.529.518.132.844.471.985.1145145
Sales YoY Gr.--14%46%-3.3%-38.6%81.2%35.2%62.2%18.3%70.3%-
Adj EPS ⓘ-9-16.4-4.4-5.9-16.2-9.5-9.73.9-2.117.114.5
YoY Gr.-NANANANANANANA-153.1%NA-
BVPS (₹) ⓘ32.542.335.329.214.15.7-4.2-4.4-8.25.3-7
Adj Net
Profit ⓘ
-5.4-16.4-4.4-5.9-16.2-9.5-9.83.9-2.117.114
Cash Flow from Ops. ⓘ3.9-3-6.56-3.94.318.2-4.160.417-
Debt/CF from Ops. ⓘ5-1.3-0.20.1-2.51.90.4-16.30.51.3-

CAGR ⓘ

9 Years 5 Years 3 Years 1 Years
Sales ⓘ22%51.6%48.4%70.3%
Adj EPS ⓘNANANANA
BVPSⓘ-18.3%-17.9%NANA
Share Price 8.2% - - -

Key Financial Parameters ⓘ

Mar'12Mar'13Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21TTM
Return on
Equity % ⓘ
-24.4-49.7-11.1-18.3-74.7-95.7-1342.6-91.333.3-1179.8-1671.7
Op. Profit
Mgn % ⓘ
-1.4-13.3-4.1-5.2-70.8-23.2-13.312.35.716.49
Net Profit
Mgn % ⓘ
-22.4-78.5-14.5-20.1-89.4-28.9-225.5-2.511.810
Debt to
Equity ⓘ
0.90.1000.71.4-1.6-15.2-3.54.1-
Working Cap
Days ⓘ
33229718919124317419516817814461
Cash Conv.
Cycle ⓘ
68392935895445305059-127

Valuation of Wintac - Consolidated

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

mw4me loader

Analyst's Notes

data not found
No data found!

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Financials

data not found
No data found!
data
No data found!
data
No data found!
data
No data found!

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Wintac Ltd FAQs

The current trading price of Wintac on 17-Dec-2020 18:59 is ₹341.6.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 16-Dec-2020 the market cap of Wintac stood at ₹342.4 Cr

The latest P/E ratio of Wintac as of 16-Dec-2020 is 23.63.

The latest P/B ratio of Wintac as of 16-Dec-2020 is -48.85.

The 52-week high of Wintac is ₹345.0 and the 52-week low is ₹336.0.

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Wintac is ₹145 ( Cr.) .

Past 10 year’s financial track record analysis by Moneyworks4me indicates that Wintac Ltd is a below average quality company.

The key valuation ratios of Wintac Ltd's currently when compared to its past seem to suggest it is in the Undervalued zone.

No data found

About Wintac Ltd

Wintac Limited was started in the year 1987 with the name of Recon Limited and as an offspring of Bangalore Pharmaceutical and Research Laboratories Pvt. Ltd which has been in existence since 1956. The company shot into prominence for launching quality products which were within the reach of common man. Over the years, Recon leveraged its expertise in launching products that encompassed a wide range of therapeutic specialties.

In 2001 -   Recon  was renamed as Wintac Limited, coined from We INtend TAking  Care (WINTAC) its range of specialties includes Antifungal, Anticancer, Cardiovascular, Corticosterid , Antiemetic, Large and small volume injectable and Ophthalmic solutions.

Wintac Limited has now forayed into the field of critical care by manufacturing and marketing products targeted to the critically ill patients. It is a fully integrated pharmaceutical company that creates, develops, manufactures and distributes healthcare products that improve the quality of life. It currently, market specialty products under a strategic alliance between Tech I Ventures Inc., USA, Alza Corporation USA and other prospective business partners. It is thus committed to meet critical health needs by providing that winning edge in critical times. its success stems from its un-wavering commitment to technology.

The state-of-the-art manufacturing plant located at the outskirts of the city of Bangalore and has been awarded the ISO 9001 certification from DNV Germany. All the products manufactured here conform to stringent quality control, recommended and specified in the U. S, British and Indian pharmacopoeia. The facility which is on 16 acres of land has a total built-up area of over 85,000 sq. ft. and consists of a capsule unit and a sterile unit. The sterile unit is about 70,000 sq. ft. including exclusive suite for Ophthalmic preparation

Product range of the company includes:

  • Antifungal- Amphocil, which contains Amphotercin B Colloidal dispersion for injection, is a novel formulation of Amphotericin B for life threatening fungal infections.
  • Anticancer- Wintac Joins the country's crusade in fighting cancer by providing high quality products at affordable prices.
  • Cardiovascular- Dobucare, which contains Dobutamine, is extensively used for short-term inotropic support in acute cardiac decompensation due to organic heart disease.
  • Corticosteroid- Metypred containing Methylprednisolone sodium succinate injection is a versatile corticosteroid of diverse utility and value in various heart diseases.
  • Antiemetic- When Cytotoxic Chemotherapy and Radiotherapy induces nausea & Vomiting in cancer Patients , Emitron effectively controls nausea and vommiting ensuring patient compliance.
  • Ophthalmics- Wide range ophthalmic preparations are available in three piece ophthalmic containers manufactured from fully automated plant.

Awards/achievements

Wintac is approved by AFSSAPS (Agence Francaise de Securite Sanitaire des Produits de Sante).

ISO 9001 certification from DNV Germany.

You have 49 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now